NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .

​   The New England Journal of Medicine: Search Results in Hematology/Oncology